Press Release · nference
nference Enters Long-Term Partnership with Cedars-Sinai to Develop AI-Enabled Platform for Advancing Clinical Research and Patient Care
Distributed by Green Web Art · Originally issued via PR Newswire

LOS ANGELES and CAMBRIDGE, Mass., Nov. 20, 2026 — nference today announced a long-term strategic collaboration with Cedars-Sinai to establish a secure platform that will help investigators analyze de-identified and multimodal clinical data. These data sets represent decades of patient care and aim to accelerate the pace of scientific innovation while amplifying research creativity.
"Understanding health and disease requires connecting what is happening across organs, across clinical modalities, and across decades of each patient's medical journey," said Venky Soundararajan, Ph.D., Founder and co-CEO of nference. "We are building a distinctive foundation for whole-body spatial intelligence to enable triangulation across disparate and unstructured modalities, so that even the most ambitious scientific questions may become more rapidly tractable and result in creative solutions for serving patients worldwide."
nference will architect the platform using its federated software that protects patient privacy, harmonizes multimodal data, and supports longitudinal curation with physician-adjudication. The nference technology transforms holistic clinical care information into rigorous research-ready data across all therapeutic, diagnostic and surgical areas. The platform will synthesize insights from all available de-identified modalities including clinical notes, laboratory results, medications, diagnostic reports, radiology and pathology imaging, genomic information, patient-consented biospecimen, electrophysiology waveforms, vitals and flowsheets. With more than a decade of longitudinal records from over 5 million patients, and frequent data refreshes as their routine care progresses over time, this "living" knowledge kernel is envisioned to help researchers gain finer-grained resolution into the inception and progression of diseases.
"We expect this collaboration with nference will provide our clinicians and scientists with new ways to learn from the collective experience of patient care, help validate scientific hypotheses and accelerate biomedical discovery," said Sumeet Chugh, MD, vice dean and chief artificial intelligence health research officer at Cedars-Sinai.
The platform is intended to support investigator-led studies, grant-funded research, education, quality improvement and collaboration with life science industry partners. It will also provide a foundation for Cedars-Sinai researchers and affiliated innovators to develop and evaluate new AI models, with the potential to inform drug discovery, clinical trial design and future diagnostics.
SOURCE nference
About nference
nference is the company advancing healthcare superintelligence as the foundational infrastructure layer for biomedical discovery and clinical research. Our multimodal AI technologies transform decades of de-identified, longitudinal clinical information into computable, actionable evidence for researchers and analysts. The nference platform synthesizes regularly refreshed evidence from routine care across billions of clinical notes, alongside patient questionnaires, laboratory tests, vital signs and flowsheet measurements, diagnostic and surgical reports, radiology and pathology imaging, electrophysiology waveforms, and genomic, transcriptomic and proteomic data derived from biospecimens collected with patient consent. To enable ambitious scientific research, nference has established long-term strategic partnerships with leading academic medical centers and integrated delivery networks, including Mayo Clinic, Duke Health, Vanderbilt University Medical Center, Emory Healthcare, Banner Health, Mercy Health, and Rush University System for Health. Through secure, agentic and federated infrastructure, nference is working to establish a gold standard for Whole-Body Spatial Computing. For more information, visit www.nference.com.